Search alternatives:
larger decrease » marked decrease (Expand Search)
less decrease » we decrease (Expand Search), levels decreased (Expand Search), largest decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
Showing 321 - 340 results of 4,620 for search 'significantly ((((((less decrease) OR (larger decrease))) OR (mean decrease))) OR (teer decrease))', query time: 0.51s Refine Results
  1. 321
    HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein.

    HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)

    Published 2024
    Save to List
    Saved in:
  2. 322
    Mean AIV-H9N2 shedding titer (Log<sub>10</sub>) in oropharyngeal swabs.

    Mean AIV-H9N2 shedding titer (Log<sub>10</sub>) in oropharyngeal swabs. by Oumayma Arbani (21001472)

    Published 2025
    Save to List
    Saved in:
  3. 323
    ECoG timescales decrease during spatial attention.

    ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

    Published 2025
    “…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”
    Save to List
    Saved in:
  4. 324
    Spatial exploration patterns of tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM).

    Spatial exploration patterns of tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

    Published 2024
    Save to List
    Saved in:
  5. 325
    Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM).

    Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

    Published 2024
    Save to List
    Saved in:
  6. 326
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 327
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 328
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 329
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 330
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 331
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 332
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 333
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 334
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 335
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 336
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 337
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 338
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 339
    Statins induced flatter neuronal somas.

    Statins induced flatter neuronal somas. by Shuk C. Tsoi (21192243)

    Published 2025
    Save to List
    Saved in:
  20. 340
    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales.

    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales. by Vincenza Tarantino (182506)

    Published 2024
    Save to List
    Saved in:

Search Tools: